ARCHIVES

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

ESAs Increase Risk of Death by 11 Percent, Blood Clots by 59 Percent, Meta-Analysis Finds; Study To Be Updated At ASCO.

June 1, 2007

Lung Cancer Size May Not Indicate Severity Of Disease

March 29, 2002

OSCC Groups Send Four Concepts To NCI Board

September 13, 1985

New Design For NCI’s CancerNet Wins Prestigious Web Site Design Awards.

November 17, 2000

Congressman Requests GAO Inquiry into FDA Foreign Inspections

April 19, 1996

Barbara Rimer Named NCAB Chairman; First Women Appointed To Lead Board

September 16, 1994